Multiple-target Therapy for Posttransplant Focal Segmental Glomerulosclerosis.

IF 1.9 Q3 TRANSPLANTATION Transplantation Direct Pub Date : 2024-05-28 eCollection Date: 2024-06-01 DOI:10.1097/TXD.0000000000001651
Juliana Mansur, Domingo Chang-Dávila, Marcela Giraldes Simões, Marina Pontello Cristelli, Suelen Bianca Stopa Martins, Henrique Machado de Sousa Proença, Laila Almeida Viana, Alexandra Nicolau Ferreira, Marisa Petrucelli Doher, José Medina-Pestana, Gianna Mastroianni Kirsztajn, Helio Tedesco-Silva
{"title":"Multiple-target Therapy for Posttransplant Focal Segmental Glomerulosclerosis.","authors":"Juliana Mansur, Domingo Chang-Dávila, Marcela Giraldes Simões, Marina Pontello Cristelli, Suelen Bianca Stopa Martins, Henrique Machado de Sousa Proença, Laila Almeida Viana, Alexandra Nicolau Ferreira, Marisa Petrucelli Doher, José Medina-Pestana, Gianna Mastroianni Kirsztajn, Helio Tedesco-Silva","doi":"10.1097/TXD.0000000000001651","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is no consensus on the ideal strategy to treat posttransplant focal segmental glomerulosclerosis. The multiple-target therapy, which consisted of high-dose intravenous cyclosporine, prednisone, and plasmapheresis, showed favorable results.</p><p><strong>Methods: </strong>This single-center, prospective study sought to evaluate the multiple-target therapy in an independent cohort of patients.</p><p><strong>Results: </strong>Thirteen patients with posttransplant focal segmental glomerulosclerosis received multiple-target therapy. Complete remission was achieved in 2 patients (15.4%), and partial remission in another 2 patients (15.4%). Four patients (30.7%) did not show remission, and 5 patients (38%) lost the graft because of posttransplant focal segmental glomerulosclerosis during the 12-mo follow-up. Premature discontinuation of treatment occurred in 10 patients (77%), all associated with infectious adverse events. Cytomegalovirus was the most common complication, and preemptive therapy was used instead of prophylaxis.</p><p><strong>Conclusions: </strong>In this cohort of patients, the efficacy of the multiple-target therapy was poor and limited by the high incidence of infectious adverse events.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11139459/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation Direct","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/TXD.0000000000001651","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There is no consensus on the ideal strategy to treat posttransplant focal segmental glomerulosclerosis. The multiple-target therapy, which consisted of high-dose intravenous cyclosporine, prednisone, and plasmapheresis, showed favorable results.

Methods: This single-center, prospective study sought to evaluate the multiple-target therapy in an independent cohort of patients.

Results: Thirteen patients with posttransplant focal segmental glomerulosclerosis received multiple-target therapy. Complete remission was achieved in 2 patients (15.4%), and partial remission in another 2 patients (15.4%). Four patients (30.7%) did not show remission, and 5 patients (38%) lost the graft because of posttransplant focal segmental glomerulosclerosis during the 12-mo follow-up. Premature discontinuation of treatment occurred in 10 patients (77%), all associated with infectious adverse events. Cytomegalovirus was the most common complication, and preemptive therapy was used instead of prophylaxis.

Conclusions: In this cohort of patients, the efficacy of the multiple-target therapy was poor and limited by the high incidence of infectious adverse events.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
移植后局灶性肾小球硬化症的多靶点疗法
背景:治疗移植后局灶节段性肾小球硬化症的理想策略尚未达成共识。由大剂量静脉注射环孢素、泼尼松和血浆置换组成的多靶点疗法显示出良好的效果:这项单中心、前瞻性研究旨在对独立患者队列中的多靶点疗法进行评估:13名移植后局灶节段性肾小球硬化症患者接受了多靶点疗法。2名患者(15.4%)获得完全缓解,另外2名患者(15.4%)获得部分缓解。4名患者(30.7%)病情未见缓解,5名患者(38%)在12个月的随访中因移植后局灶节段性肾小球硬化而失去了移植物。10名患者(77%)出现了过早中断治疗的情况,均与感染性不良事件有关。巨细胞病毒是最常见的并发症,采用的是先期治疗而非预防性治疗:结论:在这批患者中,多靶点疗法的疗效不佳,且受限于感染性不良事件的高发生率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Transplantation Direct
Transplantation Direct TRANSPLANTATION-
CiteScore
3.40
自引率
4.30%
发文量
193
审稿时长
8 weeks
期刊最新文献
Beyond 75: Graft Allocation and Organ Utility Implications in Liver Transplantation. Clinical Translation and Implementation of a Bioartificial Pancreas Therapy: A Qualitative Study Exploring the Perspectives of People With Type 1 Diabetes. Making Living-donor Liver Transplantation a Viable Option for Patients With Portopulmonary Hypertension. Outcomes of Older Primary Kidney Transplant Recipients by Induction Agent and High-risk Viral Discordance Status in the United States. Molecular Signature Associated With Acute Rejection in Vascularized Composite Allotransplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1